Luis Martinez, DO
Family Medicine · Plantation, FLNPI 1366671042
Payments from drug & device makers
Across 491 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$895
- Boehringer Ingelheim$753
- AstraZeneca$737
- Pfizer$655
- Lilly USA, LLC$449
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,473100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $1,379 |
| GSK | 54 | $895 |
| Boehringer Ingelheim | 42 | $753 |
| AstraZeneca | 46 | $737 |
| Pfizer | 38 | $655 |
| Lilly USA, LLC | 31 | $449 |
| Merck | 24 | $422 |
| Sanofi-aventis U.S. LLC | 23 | $380 |
| Kowa Pharmaceuticals America, Inc. | 17 | $335 |
| AbbVie(2 entities) | 19 | $309 |
| Amgen(2 entities) | 17 | $302 |
| Amarin Pharma, Inc. | 12 | $209 |
| Johnson & Johnson | 12 | $202 |
| Biohaven Pharmaceuticals, Inc. | 15 | $186 |
| Teva Pharmaceuticals USA, Inc. | 7 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $119 |
| Bayer | 5 | $114 |
| Astellas Pharma US Inc | 6 | $103 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $77 |
| Antares Pharma, Inc. | 3 | $67 |
| Novartis | 4 | $67 |
| Abbott | 3 | $53 |
| Heartflow, Inc. | 1 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Zyla Life Sciences, Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Halozyme Inc | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $13 |
How this compares
$8,473 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $130,856 |
| JardianceEmpagliflozin | 68 | $86,571 |
| JanuviaSitagliptin Phosphate | 52 | $56,947 |
| OzempicSemaglutide | 24 | $29,633 |
| FarxigaDapagliflozin Propanediol | 33 | $28,663 |
| EntrestoSacubitril/Valsartan | 18 | $25,830 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $23,723 |
| XareltoRivaroxaban | 18 | $22,137 |
| TradjentaLinagliptin | 24 | $20,604 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $15,992 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $12,492 |
| MounjaroTirzepatide | 11 | $11,371 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,088 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $6,559 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $5,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $655 | $130,85695 claims |
| Boehringer IngelheimJardiance, Tradjenta | $753 | $107,17592 claims |
| MerckJanuvia, Janumet | $422 | $69,43965 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $737 | $52,38552 claims |
| Novo NordiskOzempic | $1,379 | $29,63324 claims |
| NovartisEntresto | $67 | $25,83018 claims |
| Johnson & JohnsonXarelto | $202 | $22,13718 claims |
| GSKTrelegy Ellipta | $895 | $15,99213 claims |
| Lilly USA, LLCMounjaro | $449 | $11,37111 claims |
| AbbVieSynthroid | $309 | $2,92730 claims |
| Sanofi-aventis U.S. LLCLantus | $380 | $1,96616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Plantation
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.